Statement of Need

RSV infects nearly all children by the age of 2 years and, until recently, options for preventing RSV have been. RSV prevention strategies that have been developed during the last few years include passive immunization of infants via monoclonal antibodies (nirsevimab and clesrovimab) and maternal vaccination during pregnancy. As strategies and recommendations continue to evolve, healthcare providers may be challenged to remain up to date on recent evidence for the practical application of RSV prophylaxis in clinical practice and healthcare sites may experience difficulties in establishing comprehensive programs to optimize RSV prevention.

This digital QI program will provide healthcare providers and healthcare sites with the knowledge and resources necessary to apply RSV epidemiologic patterns, RSV risk factors, and options for RSV prevention within daily practice as well as facilitate optimization of processes and workflows for RSV prophylaxis.

Agenda:

Burden and Epidemiology of RSV

• Clinical and economic burden
  • Hospitalizations, ICU admissions, outpatient visits
• Long-term complications
• Historic seasonal RSV patterns
  • Impact of COVID-19, recent seasonal patterns

Risk Factors for Severe RSV Disease

• Prematurity
• Underlying medical disorders (eg, congenital heart defects, immunocompromise)
  • Congenital heart disease
• Other risk factors (eg, race/ethnicity)
• High-risk children entering their second RSV season

Preventive Therapies

• Available preventive approaches for infants
  • Maternal vaccination, monoclonal antibodies
• Comparison of monoclonal antibodies
  • MOAs, dosing and administration, available data on effectiveness and safety
• Guideline recommendations
  • Who should be immunized and when

Implementation Protocols and Pathways

• Examples of RSV prophylaxis protocols from various countries
• Becoming a VFC-enrolled birthing hospital
  • Benefits
  • Example protocols and workflows
• HCP-led RSV prophylaxis services
• Insurance/billing processes
• Product storage/handling and management

Parent/Caregiver Communication Strategies and Education

• Navigating questions about ACIP, AAP, and ACOG recommendations
• Common questions and answers
• Strategies for overcoming vaccine hesitancy
  • Motivational interviewing

Target Audience

This activity is intended for pediatricians, family medicine practitioners, pediatric nurses and nurse practitioners, pediatric hospitalists, neonatologists, newborn nursery practitioners, pharmacists, obstetrician/gynecologists, midwives.

Learning Objectives

Upon completion of this activity, learners will be able to:

• Develop continuous team training interventions to interpret and apply the latest clinical evidence around RSV immunization practices
• Employ evidence-based protocols across care settings to align with the latest guideline recommendations for preventing RSV in infants and children
• Establish comprehensive, multidisciplinary clinical pathways to mitigate barriers to ensuring equal protection from RSV through access to long-acting monoclonal antibody therapies
• Adopt parent-centric, culturally competent communication and education materials to explain the clinical and economic impact of RSV and importance of immunization

Method of Participation

To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view the online interventions; and return after 30 days to report progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.

ABIM credit will be submitted to ABIM within 30 days of completion.

Accreditation and Credit Designation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this Enduring Material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Physician assistants (PAs) and nurse practitioners (NPs) may participate in this educational activity and earn a certificate of completion as AAPA and AANP accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Rush University Medical Center designates this application-based activity for a maximum of 2.5 contact hour(s) for pharmacists. ACPE Universal Activity Number:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Disclosures

It is the policy of the Interprofessional Continuing Education office at Rush to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. RUSH asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.

Individuals in control of content for this activity have the following relevant financial relationships with ineligible companies to disclose and all financial relationships have been mitigated.

The following financial relationships have been provided:

Kevin Ault, MD, FACOG, FIDSA
Nothing to disclose

Kaitlyn Rivard, PharmD, BCIDP
Consultant: Field Quest, Office Hours, Wolters Kluwer. Other: Pfizer

Brianna Johnson, DNP
Nothing to disclose

Staff and Reviewer Disclosures

Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None

Acknowledgement

This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Sanofi US.